GÖTEBORG, Sweden--(BUSINESS WIRE)-- Meda’s (STO:MEDAA) partner for retigabine, Valeant Pharmaceuticals International, Inc., today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion, recommending marketing authorization for retigabine, named ezogabine in the US, as an adjunctive (add-on) treatment of partial onset seizures, with or without secondary generalisation in adults aged 18 years and above with epilepsy.
